Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma

被引:169
|
作者
Kwong, DLW
Sham, JST
Leung, LHT
Cheng, ACK
Ng, WM
Kwong, PWK
Lui, WM
Yau, CC
Wu, PM
Wei, W
Au, G
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2006年 / 64卷 / 02期
关键词
dose escalation; IMRT; nasopharyngeal carcinoma;
D O I
10.1016/j.ijrobp.2005.07.968
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To study the safety and efficacy of dose escalation in tumor for locally advanced nasopharyngeal carcinoma (NPC). Methods and Materials: From September 2000 to June 2004, 50 patients with T3-T4 NPC were treated with intensity-modulated radiotherapy (IMRT). Fourteen patients had Stage III and 36 patients had Stage IVA-IVB disease. The prescribed dose was 76 Gy to gross tumor volume (GTV), 70 Gy to planning target volume (PTV), and 72 Gy to enlarged neck nodes (GTVn). All doses were given in 35 fractions over 7 weeks. Thirty-four patients also had concurrent cisplatin and induction or adjuvant PF (cisplatin and 5-fluorouracil). Results: The average mean dose achieved in GTV, GTVn, and PTV were 79.5 Gy, 75.3 Gy, and 74.6 Gy, respectively. The median follow-up was 25 months, with 4 recurrences: 2 locoregional and 2 distant failures. All patients with recurrence had IMRT alone without chemotherapy. The 2-year locoregional control rate, distant metastases-free and disease-free survivals were 95.7%, 94.2%, and 93.1%, respectively. One treatment-related death caused by adjuvant chemotherapy occurred. The 2-year overall survival was 92.1%. Conclusions: Dose escalation to 76 Gy in tumor is feasible with T3-T4 NPC and can be combined with chemotherapy. Initial results showed good local control and survival. (C) 2006 Elsevier Inc.
引用
收藏
页码:374 / 381
页数:8
相关论文
共 50 条
  • [31] Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma
    Kim, Jeong Eun
    Ryoo, Baek-Yeol
    Ryu, Min-Hee
    Chang, Heung-Moon
    Suh, Dong Jin
    Lee, Han Chu
    Lim, Young-Suk
    Kim, Kang Mo
    Kang, Yoon-Koo
    ONCOLOGY, 2012, 82 (02) : 119 - 125
  • [32] Preliminary results of a randomized study (NPC-9902 trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma
    Lee, Anne W. M.
    Tung, Stewart Y.
    Chan, Anthony T. C.
    Chappell, Rick
    Fu, Yiu-Tong
    Lu, Tai-Xiang
    Tan, Terence
    Chua, Daniel T. T.
    O'Sullivan, Brian
    Xu, Shirley L.
    Pang, Ellie S. Y.
    Sze, Wai-Man
    Leung, To-Waj
    Kwan, Wing-Hong
    Chan, Paddy T. M.
    Liu, Xiu-Fang
    Tan, Eng-Huat
    Sham, Jonathan S. T.
    Siu, Lillian
    Lau, Wai-Hon
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (01): : 142 - 151
  • [33] Proton and carbon ion radiation therapy for locally advanced pancreatic cancer: A phase I dose escalation study
    Yu, Zhan
    Hong, Zhengshan
    Zhang, Qing
    Lin, Lien-Chun
    Shahnazi, Kambiz
    Wu, Xiaodong
    Lu, Jiade
    Jiang, Guoliang
    Wang, Zheng
    PANCREATOLOGY, 2020, 20 (03) : 470 - 476
  • [34] Evaluation of automatic VMAT plans in locally advanced nasopharyngeal carcinoma
    Quanbin Zhang
    Liya Ou
    Yingying Peng
    Hui Yu
    Linjing Wang
    Shuxu Zhang
    Strahlentherapie und Onkologie, 2021, 197 : 177 - 187
  • [35] Prognostic value of sarcopenia in the patients with locally advanced nasopharyngeal carcinoma
    Liu, Ting
    Wang, Guimei
    Chen, Chunmei
    He, Lihe
    Wang, Rensheng
    JAPANESE JOURNAL OF RADIOLOGY, 2024, 42 (09) : 1047 - 1057
  • [36] Which chemotherapy to associate with IMRT in locally advanced nasopharyngeal carcinoma?
    Nouri, Omar
    Ben Ali, Balkiss
    Mnejja, Wafa
    Fourati, Nejla
    Siala, Wicem
    Khanfir, Afef
    Sahnoun, Tarek
    Farhat, Leila
    Daoud, Jamel
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S1415 - S1417
  • [37] Locally advanced nasopharyngeal carcinoma: Current and emerging treatment strategies
    Perri, Francesco
    Bosso, Davide
    Buonerba, Carlo
    Di Lorenzo, Giuseppe
    Scarpati, Giuseppina Della Vittoria
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2011, 2 (12): : 377 - 383
  • [38] Timing of chemoradiotherapy and patient selection for locally advanced nasopharyngeal carcinoma
    Sanguineti, G
    Bossi, P
    Pou, A
    Licitra, L
    CLINICAL ONCOLOGY, 2003, 15 (08) : 451 - 460
  • [39] Paclitaxel with cisplatin in concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma
    He, Xia-Yun
    Hu, Chao-Su
    Ying, Hong-Mei
    Wu, Yong-Ru
    Zhu, Guo-Pei
    Liu, Tai-Fu
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2010, 267 (05) : 773 - 778
  • [40] Paclitaxel with cisplatin in concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma
    Xia-Yun He
    Chao-Su Hu
    Hong-Mei Ying
    Yong-Ru Wu
    Guo-Pei Zhu
    Tai-Fu Liu
    European Archives of Oto-Rhino-Laryngology, 2010, 267 : 773 - 778